Detalhe da pesquisa
1.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
; 149(3): 192-203, 2024 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632469
2.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
3.
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
N Engl J Med
; 384(14): 1312-1322, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626252
4.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
N Engl J Med
; 384(2): 105-116, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185990
5.
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
Am Heart J
; 269: 179-190, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38160917
6.
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial.
Am Heart J
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740532
7.
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
J Card Fail
; 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215932
8.
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.
J Card Fail
; 30(1): 26-35, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683911
9.
Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial.
J Card Fail
; 30(4): 525-537, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820896
10.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879424
11.
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
Eur Heart J
; 44(31): 2947-2962, 2023 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37217188
12.
Diet, cardiovascular disease, and mortality in 80 countries.
Eur Heart J
; 44(28): 2560-2579, 2023 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414411
13.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770629
14.
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
Lancet
; 400(10367): 1938-1952, 2022 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356631
15.
Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.
Lancet
; 400(10355): 811-821, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36088949
16.
Rivaroxaban in Peripheral Artery Disease after Revascularization.
N Engl J Med
; 382(21): 1994-2004, 2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32222135
17.
Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy.
Eur Heart J
; 43(30): 2841-2851, 2022 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325078
18.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427295
19.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922353
20.
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Eur Heart J
; 43(23): 2212-2220, 2022 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325102